Skip to main content
Panagiotis Konstantinopoulos, MD, Oncology, Boston, MA

Panagiotis Konstantinopoulos MD PhD

Gynecologic Cancer, Hematologic Oncology


Velma Eisenson Endowed Chair for Clinical and Translational Research, Director Mellen and Eisenson Family Center for BRCA and Related Genes Dana-Farber Cancer Institute, Professor of Medicine Harvard Medical School

Join to View Full Profile
  • 450 Brookline AveBoston, MA 02215

Dr. Konstantinopoulos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Panagiotis (Panos) Konstantinopoulos, MD, PhD is Director of the Mellen and Eisenson Family Center for BRCA and Related Genes and Director of Translational Research, Division of Gynecologic Oncology. He is also the Velma Eisenson Endowed Chair for Clinical and Translational Research at DFCI and Professor of Medicine at Harvard Medical School. His clinical and translational research career focuses on ovarian and endometrial cancers with a focus on the areas of DNA Damage and Repair and Immunotherapy. His research efforts in this area have been supported by the Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), the American Association of Cancer Research (AACR) and the NIH/NCI. As a clinical researcher, he is involved as a principal investigator (PI) and co-investigator in multiple gynecologic cancer clinical trials and serves as Co-Chair of the NRG Development Therapeutics (Translational Science) Committee. After receiving his MD and PhD from University of Patras in Greece, Dr Konstantinopoulos completed internship and residency at State University of New York at Syracuse, followed by a medical oncology fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. He also received a Master's degree in Clinical Investigation from Harvard Medical School and Massachusetts Institute of Technology (MIT) Department of Health Sciences and Technology.

Education & Training

  • Harvard - MIT Health Sciences and Technology
    Harvard - MIT Health Sciences and TechnologyMMSc, Clinical Investigation, 2008 - 2010
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityResidency, Internal Medicine, 2002 - 2005
  • University of Patras School of Medicine
    University of Patras School of MedicineClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • MA State Medical License
    MA State Medical License 2005 - 2025
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutate... 
    2019 ASCO Annual Meeting - 6/1/2019
  • TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian ca... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Press Mentions

  • New Class of Cancer Drug Halts Tumor Growth in Early Human Trials
    New Class of Cancer Drug Halts Tumor Growth in Early Human TrialsJune 23rd, 2020
  • New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP Combo
    New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
  • Avelumab Active in Mismatch Repair-Deficient Endometrial Cancer
    Avelumab Active in Mismatch Repair-Deficient Endometrial CancerOctober 3rd, 2019
  • Join now to see all

Grant Support

  • Targeting Replication Stress and DNA Damage Response in Uterine CancerDANA-FARBER CANCER INST2024–2029
  • Targeting CDK7 in CCNE1-amplified Ovarian CancerSTANFORD UNIVERSITY2022–2027
  • Targeting CDK7 in CCNE1-amplified Ovarian CancerSTANFORD UNIVERSITY2022–2027

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: